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Background. To date, video capsule endoscopy (VCE) is still contraindicated by the FDA and the main manufacturers of Cardiac
Implantable Electronic Devices (CIED) in patients with CIED, given a theoretical electromagnetic interference and possible device
malfunction. Objectives. The objective of this study was to assess the safety profile and efficacy of VCE in patients with implantable
cardiac devices through analyzing the risk of mutual interference. Methods. A systematic review of PubMed, Web of Science,
and Embase databases was conducted. Peer-reviewed original articles, published in the English language and containing “capsule
endoscopy” AND “pacemaker”, “defibrillator” OR “left ventricular assist device” as keywords, were selected. Studies performed
in vitro, isolated case reports, and abstracts/posters were excluded. Results. A total of 735 VCE procedures were performed in
patients with cardiac devices in various clinical settings. Cardiac events were not seen in any case. Interference on capsule images
transmission was noted in 5 cases (left ventricular assist device (LVAD)) where few images were lost when the capsule was closest
to the device. Finally, interference between capsule and telemetry leads was noted in 6 cases (4 Permanent Pacemakers (PPM), 2
Implantable Cardioverter-Defibrillator (ICD)) leading to image artifacts. Discussion. Adverse cardiac events were not seen in any
study. Loss of images occurred when the VCE was in proximity to the device (only with LVAD) or after telemetry leads installation
without affecting the completion rate and diagnostic yield of VCE. Conclusion. VCE is safe and remains efficient in patients with
cardiac devices. If cardiac monitoring is required, wired systems are preferable.

1. Introduction
Gastrointestinal bleeding that persists or recurs without any
obvious etiology after performing an upper endoscopy and
colonoscopy originates from the small bowel (SB) in the
majority of cases [1]. The gold standard test for suspected
SB bleeding is video capsule endoscopy (VCE). It was first
introduced into clinical practice in 2001 and has emerged
given its noninvasiveness and effectiveness as it allows the
examination of the entire length of the SB with high quality
image acquisition. It is contraindicated in patients with
suspected partial or intermittent SB obstruction and pregnant
women. A significant proportion of patients presenting with
suspected SB bleed have implantable cardiac devices. The use

of VCE in this population has been subject to debate given the
possible electromagnetic interference. In 2009, the European
Society of Gastrointestinal Endoscopy (ESGE) recommended
the use of VCE in patients with Permanent Pacemakers
(PPM) and Implantable Cardioverter-Defibrillators (ICD)
[2]. However, VCE in patients with PPM or ICD is still
contraindicated according to the last US Food and Drug
Administration (FDA) update issued on November 28, 2001,
[3] and to the main manufacturers recommendations.

2. Video Capsule Endoscopy System
Video Capsule Endoscopy is performed using an ingestible
imaging capsule that passes naturally through the
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gastrointestinal tract, capturing and transmitting video
images along its way, to an array of electrodes affixed to the
patient’s thorax. These electrodes detect data signals and
send them directly to an external recording device, which
collects and stores the video images to be downloaded to a
computer workstation for review and diagnosis. The available
capsules on the market are PillCam SB (Given Imaging
Ltd), EndoCapsule (Olympus), MicroCam (IntroMedic),
and OMOM small-bowel capsule (Chongqing Jinshan
Science and Technology Group).

3. Electromagnetic Interference
The implantation of PPM and ICD for the treatment of bradyand tachy-arrhythmia has increased significantly over the
last 30 years [4]. Likewise, there has been an increase in
the development and use of technology that emits electromagnetic radiations that may disturb the behavior of cardiac
implantable electronic devices (CIED) with potential harmful
consequences. Because one of the most essential components
of CIED function is accurate sensing of intrinsic cardiac
potentials, any interference by nonphysiologic sources may
cause the system to interpret such interference as cardiac
in nature [4]. This noise sensing can have drastic adverse
clinical consequences, such as the failure to pace when
needed, or the triggering of ICD therapies due to inappropriate identification of noise as ventricular tachycardia or
ventricular fibrillation [4]. This interference between two
separate electronic devices is called electromagnetic interference (EMI). The sources of EMI can be related to everyday-use devices like cellular phones and metal detectors [4]
or can be iatrogenic like radiation therapy, electrocautery,
transcutaneous electric nerve stimulation, electroconvulsive
therapy, and magnetic resonance imaging [4]. Video capsule
generates an electromagnetic field and theoretically can be
a source of EMI with implantable cardiac devices having
possible consequences on patients.
We performed this pooled analysis of the published
literature in order to investigate the efficacy and safety of
VCE in patients with implantable cardiac devices including
Permanent Pacemakers (PPM), Implantable CardioverterDefibrillators (ICD) and Left Ventricular Assist Devices
(LVAD).

4. Materials and Methods
Articles published in English language on VCE and
implantable cardiac devices from 1/1/04 till 9/1/17 were
searched through PubMed, Web of Science, and Embase databases using the keywords (MeSH terms): “video capsule
endoscopy” OR “capsule endoscopy” OR “wireless capsule
endoscopy” OR “wireless capsule endoscope” OR “capsule
endoscope” OR “video capsule endoscope” OR “video
capsule”; combined with either: “heart devices”, “pacemaker”; “defibrillator”, “assist device”, or “heart” AND
“Interference”. The title and abstracts of the retrieved publications were reviewed and screened initially. Then, data
selection occurred after manuscript review. Studies focusing
on capsule endoscopy used in conjunction with the presence
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of cardiac implantable device: pacemaker and/or defibrillator
and/or left ventricular assist device in vivo were analyzed.
In the case of duplicate studies, the most recent study
including the latest series of patients was retained. Isolated
case reports, letters to the editors, and review articles were
excluded (Figure 1).
Data on patients’ demographics, indications for video
capsule endoscopy, technical complications, and diagnostic
and completion rates were collected. The main outcome
was the safety of the VCE procedure defined as the successful completion of video capsule endoscopy without cardiac adverse events or cardiac device malfunction. Cardiac
adverse events included arrhythmias during VCE and a
change in the cardiac device settings after VCE. Secondary
outcome included the quality of the transmitted images
reflecting interference of the implantable cardiac devices with
the VCE, completion rate and diagnostic rate. Data was
analyzed using SPSS software.

5. Results
A total of 16 original articles (10 retrospective and 6 prospective studies) [5–20], involving a total of 735 VCE procedures,
were included in our analysis. The selected publications were
sorted per year. The number of publications per year has
notably increased from 2011 through 2016 (Figure 2).
This increase in the number of studies might correlate with the publication of the recommendations by the
European Society of Gastrointestinal Endoscopy (ESGE) in
2009 allowing more patients with implantable cardiac devices
to get VCE procedures and thus increasing the studied
population number and studies.
5.1. Baseline Characteristics. Table 1 recapitulates the 16 studies included in the final analysis along with the baseline
characteristics of the population. The majority of VCE procedures were performed in patients with PPM (487 out of
735 procedures), followed by ICDs (162 procedures). 86 of
the 735 procedures were performed in patient with LVADs.
The most common PPM used was Medtronic (43% of
all PPM) followed by Guidant (30% of all PPM). Among
ICDs, Medtronic (31%) was primarily used, followed by
St Jude (27%) and Guidant (21%). Finally, 92% of the
LVAD studied were Thoratec HeartMate II. The three main
capsules used in the selected studies were PillCam (93%),
EndoCapsule (6%), and MiroCam (1%). The OMOM
capsule was not studied in any of the selected publications.
The pooled median age of the included patients was 69.8
years with 64% of males and 36% of females. The most
common indication for VCE was gastrointestinal bleeding
(76%) including both overt and occult bleeding. In 20% of
patients the indication for VCE was iron deficiency anemia.
The remaining (4%) had various other indications such as
chronic abdominal pain, celiac disease, Peutz-Jeghers disease,
and Crohn’s disease. The pooled completion rate of VCE in
patients with cardiac devices was 85% and the diagnostic yield
of VCE in this population was 70%.
5.2. Cardiac Outcome and Quality of the Transmitted Images.
The pooled adverse cardiac events rate was 0%, as well

Canadian Journal of Gastroenterology and Hepatology

Identiﬁcation

Articles identiﬁed
on PubMed
(n = 94)
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Articles identiﬁed
on Web of Science
(n = 153)

Articles identiﬁed
on Embase
(n = 260)

Total articles identiﬁed
(n = 507)

Screening

Articles after duplicates removed
(n = 303)

Articles screened
(n = 303)

Included

Eligibility

Articles assessed
for eligibility
(n = 60)

Articles excluded after
screening by title/abstract
(n = 243)

Articles excluded (n = 44)
Posters/Abstracts only (n = 17)
Letters to the editors (n = 5)
Duplicate population (n = 10)
Case reports (n = 10)
Studies in vitro (n = 2)

Articles included in
the ﬁnal analysis
(n = 16)

Figure 1: PRISMA diagram showing the selection process of the articles included in the final analysis.
Table 1: Studies included in the analysis and the baseline characteristics of the patients.
Study
Leighton [5]
Payeras [6]
Dubner [7]
Leighton [8]
Dirks [9]
Elias [10]
Bandorski [11]
Chung [12]
Bandorski [13]
Cuschieri [14]
Harris [15]
Stanish [16]
Moneghini [17]
Amornsawadwattana [18]
Truss [19]
Hanson [20]
Pooled numbers

Year
2004
2005
2005
2005
2008
2009
2011
2012
2012
2012
2013
2014
2016
2016
2016
2016

n
5
20
6
5
5
4
59
6
380
20
118
21
14
30
8
34
735

Mean age
73
78
61
72
45
78
73
60.5
n/a
71
72
71.1
66.4
60.1
63
67.1
69.8

Male
4/5 (80%)
14/20 (70%)
4/6 (66%)
1/5 (20%)
0/5 (0%)
2/4 (50%)
n/a
3/6 (50%)
n/a
13/20 (65%)
74/118 (63%)
8/21 (38%)
11/14 (78%)
24/30 (80%)
8/8 (100%)
n/a
166/262 (64%)

as the pooled cardiac device malfunction rate. No oversensing by PPMs or delivery of inappropriate shock by
ICDs was noted. Supraventricular and/or ventricular premature contraction occurred in two patients without any
clinical symptom. These two patients had similar arrhythmias detected on their baseline electrocardiogram prior to

Female
1/5 (20%)
6/20 (30%)
2/6 (34%)
4/5 (80%)
5/5 (100%)
2/4 (50%)
n/a
3/6 (50%)
n/a
7/20 (35%)
44/118 (37%)
13/21 (62%)
3/14 (22%)
6/30 (20%)
0/8 (0%)
n/a
96/262 (36%)

Completion rate
5/5 (100%)
20/20 (100%)
n/a
n/a
5/5 (100%)
n/a
n/a
6/6 (100%)
n/a
n/a
79/118 (67%)
20/21 (95%)
13/14 (92.8%)
30/30 (100%)
8/8 (100%)
34/34 (100%)
220/261 (85%)

Diagnostic rate
n/a
14/20 (70%)
n/a
n/a
5/5 (100%)
n/a
n/a
n/a
n/a
n/a
n/a
13/21 (62%)
9/14 (64.2%)
12/30 (40%)
8/8 (100%)
31/34 (91%)
92/132 (70%)

VCE. In one case, the video capsule showed low signal
resulting in a transient lack of localization of the capsule without any loss of images (Video capsule: PillCam;
PPM: ELA Sorin). Some impairment of the quality of
VCE images consisting of artifacts and/or recording gaps
occurred in 6 patients (4 PPM and 2 ICD, 0.8% overall)
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Table 2: Pooled results of the 16 studies included in the analysis [5–20].

Type of
Device

Total Number
of cardiac
devices (n)

PPM

487

ICD

162

LVAD

86

Cardiac devices
brand
Medtronic (77)
Guidant (54)
St Jude Medical (26)
Biotronik (12)
Vitatron (8)
ELA Sorin (3)
Boston scientific (1)
No specification
(306)
Medtronic (15)
St Jude (13)
Guidant (10)
Boston scientific (7)
ELA Sorin (2)
Biotronik (1)
No specification
(114)
Thoratec HeartMate
II (35)
HeartWare (3)
No specification (48)

VCE brand

Cardiac Outcome

Quality of transmitted images

No adverse cardiac events
No cardiac device
PillCam (431)
malfunction
EndoCapsule (33)
1 case had some atrial and
MiroCam (3)
ventricular premature
No specification
contractions without
(20)
clinical symptoms

4 cases of VCE interference with
telemetry leads leading to few images
loss
1 case showed low capsule signal
resulting in transient lack of
localization of the capsule without
images loss (PillCam with ELA Sorin)

PillCam (147)
EndoCapsule (8)
MiroCam (3)
No specification
(4)

No adverse cardiac events
No cardiac device
malfunction
1 case had some atrial and
ventricular premature
contractions without
clinical symptoms

2 cases of VCE interference with
telemetry leads leading to few images
loss

PillCam (52)
No specification
(34)

No adverse cardiac events 5 cases of possible interference leading
to images loss/artifact when VCE was
No cardiac device
near the device
malfunction

Permanent Pacemaker (PPM); Implantable Cardiac Defibrillator (ICD); Left Ventricular Assist Device (LVAD); Video Capsule Endoscopy (VCE).

and this happened only after the installation of the telemetry leads. Finally, artifacts in the capsule images occurred
in five patients with LVAD (0.6% overall; 5.8% among
patients with LVADs) when the capsule was in the upper
abdomen without any cardiac device malfunction or arrhythmia occurrence. Table 2 summarizes the VCE procedures,
cardiac outcome, and quality of the transmitted images.

Number of articles (n)
6
5
4
3

6. Discussion
2

The feasibility and safety of wireless video capsule endoscopy
in patients with cardiac devices have been called into doubt
since its introduction in 2001 by extrapolation to the early
negative experiences of cardiac device malfunction with
magnetic resonance imaging and electrocautery current.
However, the benefits of identifying the source of bleed in
patients with cardiac devices are not to be ignored. Especially, patients with cardiac devices mostly have advanced
heart disease, dilated cardiomyopathies, and coronary artery
disease making of them the candidates par excellence to
receive antiplatelets and/or anticoagulants and to be at risk
for gastrointestinal bleeding and undergo the ensuing workup. There has been a growing interest in assessing the safety
and feasibility of VCE in this population that was reflected
by the increasing number of clinical studies over the recent
years. Theoretically, electromagnetic interference between
both devices is possible and its impact on either of the
devices is yet to be determined [4]. However, interference
with the cardiac devices is not an expected event physically,
given that the signal magnitude from the capsule recorder is
too low to interfere with PPMs/ICDs, in addition to several

1
0
2002-2004

2005-2007

2008-2010

2011-2013

2014-2016

Number of articles (n)

Figure 2: Number of published articles by year showing increasing
interest in this topic.

safety mechanisms that isolate most of the manufactured
pacemakers/defibrillators from their surroundings such as
the hermetically sealed titanium housing around the device,
the bipolar mode programming, and the provision of filters
in the amplifier [4].
Following initial reports of uneventful VCE in patients
with cardiac devices, many centers worldwide started performing VCE in this population. Various types and brands
of cardiac devices were used in combination with different
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brands of video capsules. The most commonly used capsules
and heart devices suggesting a more solid evidence of safety
were the PillCam (Given Imaging) and EndoCapsule
(Olympus) with PPMs and ICDs from Medtronic, St Jude,
and Guidant and Thoratec HeartMate II LVAD. This can
be nothing but the reflection of the earlier introduction of
these brands to the market than the other studied capsules
and devices chronologically.
In an effort to address the safety profile, our pooled
analysis of clinical studies did not detect any serious adverse
cardiac events. In two cases, atrial and ventricular premature
contractions were observed without any clinical significance
or impact. In fact, these two patients had similar arrhythmias
detected on their baseline electrocardiograms prior to VCE.
The most common indication for VCE in our select
population of patients with implantable cardiac devices was
obscure gastrointestinal bleeding (76%). This proportion is
comparable to the results found by Liao et al. (2010) who
performed a pooled analysis of 22,840 small-bowel capsule
endoscopy procedures for the evaluation of patients with
small-bowel signs and symptoms, with the most common
indication being obscure GIB (66%) [21]. The pooled completion rate of VCE in our patient population was 85%
and the detection rate of VCE was 70% comparable to the
overall pooled completion rate of 83.5% (83.6% for OGIB)
and a pooled detection rate of 59.4% overall (60.5% for
OGIB) in the studied general population of Liao et al. (2010),
respectively [21].
Some interference has been observed in image transmission leading to the loss of few images when the VCE
was in proximity to the device (in the distal esophagus and
stomach mainly) or after telemetry leads installation with
a pooled “interference with image transmission” of 1.4%
overall. In half of these cases, the interference with image
transmission was related to the telemetry leads rather than
the cardiac device per se. It is worth pointing out that this
low interference with image transmission did not affect the
completion rate or the diagnostic yield of the isolated nor
overall procedures and this was reflected by the comparable
rates of completion and detection to the general population
as mentioned previously [21]. Given that interference was
noted in isolated cases between VCE and telemetry systems,
a wired system of monitoring would be preferable if cardiac
monitoring is required by the local policy of the center or at
the discretion of the physician.
Another observation is worth noting concerning the
MicroCam (IntroMedic) which uses electric-field propagation system to transmit the images instead of the traditional radiofrequency signal transmission. Chung et al.
(2012) prospectively studied this brand of video capsule in
6 patients (3 PPM and 3 ICD) [12]. It was suggested that
even with the human body communication technique, data
transmission was safe and effective. No disturbances in PPM
or ICD function were identified and the images transmitted
remained of good quality [12]. Nevertheless, the data on
the MicroCam remains much less solid compared to the
PillCam and EndoCapsule because of the very small
number of procedures (1% of the total VCE) performed with
this brand of capsule.

5
Several limitations might have hurdled this pooled analysis, mainly the low power of isolated studies and the
retrospective design and observational nature of the analyzed
studies. Also, the myriad of brands and types of cardiac
devices and capsules limit the generalization of the results.
However, this study represents the first pooled analysis on the
subject reflecting clinical data and providing evidence of safe
and efficient use of VCE in this disadvantaged population.
Solid evidence does not exist to undermine the use of
diagnostic means guiding further management and possible
outcome in patients with cardiac devices undergoing video
capsule endoscopy.

7. Conclusion
According to available data, VCE can be performed safely
and efficiently in patients with cardiac devices. Nevertheless,
electromagnetic interference can occur between VCE and
LVADs and with wireless telemetry leads causing impairment
of the recordings and leading to some artifacts and gaps but
without affecting the diagnostic yield of the procedure or the
cardiac safety of patients. If cardiac monitoring is required,
wired systems are preferable.
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